Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Published on October 3, 2012 at 2:49 AM · 2 Comments

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced commencement of a Phase 2 study of a d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no approved amphetamine-based transdermal treatment option available for ADHD.

The Phase 2 study is a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of d-ATS compared to placebo in subjects between 6 and 17 years of age. The study is expected to enroll approximately 90 subjects at up to 5 study sites and is scheduled to conclude in the second quarter of 2013. Additional information on the Phase 2 study will be made available on    


Noven Pharmaceuticals, Inc.   

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
  1. Luna Luna Canada says:

    What to do when meds have had a bad effect on a person with ADHD?

  2. Luna Luna Canada says:

    why are adhd symptoms so often though as possible schizophrenia?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Transplanted human stool may offer treatment hope for ulcerative colitis patients